

Index

ABBREVIATED BIOLOGICS LICENSE APPLICATIONS (aBLAs)

- Generally, § 3:3, 3:6 to 3:14
- Better than reference product, consequences, § 3:10
- BPCIA, jurisdiction before submission of aBLA, § 4:1
- Clinical trials, § 3:8
- Demonstrating biosimilarity requirements, § 3:6 to 3:11
- Exclusivity, interchangeable product, § 3:12
- Interchangeability, demonstrating, § 3:11, 3:12
- Labeling requirements for biosimilar and interchangeable biosimilar products, § 3:13
- Manufacturing information, § 3:7
- No patent linkage, § 3:14
- Proving biosimilarity, § 3:9
- Reference product, consequences of comparison, § 3:10
- Worse than reference product, consequences, § 3:10

ANTICIPATION

- Validity, ineligible subject matter, § 4:82

ANTITRUST ACTIONS

- Generally, § 8:1 to 8:6
- Acquisition and enforcement of intellectual property
 - patent thickets, § 8:5
 - sham litigation, § 8:4
 - walker process fraud, § 8:4
- Challenges to patent settlement agreements, § 8:2
- Enforcement. Acquisition and enforcement of intellectual

ANTITRUST ACTIONS—Cont'd

- property, above
- Exclusionary contracting and rebating strategies, § 8:6
- Filing agreements with government, § 8:3

APPEALS

- Post-grant proceedings, § 5:20

APPLICATION TYPES

- Abbreviated Biologics License Applications (aBLAs), § 3:3
- Approved NDAs for biological products, deemed to be BLAs, § 3:5
- Biologics License Applications (BLAs), § 3:2
- Drug products not regulated as biological products, § 3:4

APPROVAL

- FDA Approval (this index)

APPROVED (NDAs) FOR BIOLOGICAL PRODUCTS, DEEMED TO BE (BLAs)

- NDAs to BLAs, conversion, § 3:5

ATTORNEYS' FEES

- Remedies, enforceability of patent, § 4:96

BIOBETTERS

- Generally, § 3:15

BIOLOGICS LICENSE APPLICATIONS (BLAs)

- Generally, § 3:2

BIOLOGICS PRICE COMPETITION AND INNOVATION ACT (BPCIA)

- Generally, § 2:1, 4:1 to 4:98

BIOLOGICS PRICE

COMPETITION AND INNOVATION ACT (BPCIA) —Cont'd

Discovery
generally, § 4:61 to 4:68
confidentiality tiers, § 4:68
expedited discovery, § 4:64
manufacturing information,
§ 4:62
overlapping patents-in-suit,
§ 4:63
preliminary injunction, § 4:64
prosecution bars, § 4:66
protective orders, § 4:65 to 4:68
regulatory bars, § 4:67
same biological product, § 4:63
Newly issued or licensed patents,
§ 4:21
Notice of Commercial Marketing
(NCM) (this index)
Patent Dance (this index)
Patent Infringement Liability (this
index)
Post-Grant Proceedings (this
index)
Preliminary injunctions, § 4:58,
4:64
Remedies (this index)
Scheduling, staging and consolida-
tion, § 4:59
Scheduling and staging, § 4:60

CITIZEN PETITIONS

FDA approval process, § 3:23

COMMENCEMENT OF SUIT

Generally, § 4:32 to 4:57
Declaratory Judgment Action (this
index)
Jurisdiction (this index)
Jury Trial (this index)
Limitation on claims
generally, § 4:51 to 4:54
failure of applicant to provide
notice, § 4:52
first wave litigation, § 4:53

COMMENCEMENT OF SUIT

—Cont'd

Limitation on claims—Cont'd
scope-limiting ability of
applicant, § 4:53
second wave litigation, § 4:54
Standing, § 4:42
Venue (this index)

CONFIDENTIAL INFORMATION

Patent Dance (this index)
Protective orders, confidentiality
tiers, § 4:68

CONSTRUCTION

Patent infringement liability, claim
construction, § 4:70

CONTINUED PROSECUTION

Prosecution of biologic patents,
§ 1:10

COUNTERCLAIMS

Reference product sponsor (RPS),
right to bring declaratory
judgment action, § 4:49

DECLARATORY JUDGMENT ACTION

Reference product sponsor (RPS),
right to bring
262(l)(9)(A), § 4:46
262(l)(9)(B), § 4:45
262(l)(9)(C), § 4:44 to 4:46
generally, § 4:43 to 4:50
counterclaims, application to,
§ 4:49
discretionary exercise of
declaratory judgment juris-
diction, § 4:50
limits on ability of applicants to
seek declaratory relief,
§ 4:47
non-jurisdictional treatment by
courts, § 4:48
timing of suit, § 4:46
Venue, § 4:37 to 4:39

INDEX

DISCOVERY

- Biologics Price Competition and Innovation Act (BPCIA) (this index)
- Foreign litigation
 - generally, § 7:1 to 7:4
 - discretion, § 7:4
 - ex parte application, § 7:3
 - Section 1782 Action, § 7:2 to 7:4

DOCTRINE OF EQUIVALENTS

- Patent infringement liability, direct infringement, § 4:76

DOUBLE PATENTING

- Obviousness-type, § 4:85

ENFORCEMENT AND ENFORCEABILITY

- Antitrust Actions (this index)
- Intellectual property acquisition and enforcement. Antitrust Actions (this index)
- NCM provisions, § 4:26
- Patent dance, confidential information, § 4:13
- Patent Infringement Liability (this index)
- Remedies (this index)

ENSNAREMENT

- Patent infringement liability, direct infringement, § 4:78

ESTOPPEL

- Generally, § 5:13 to 5:16
- Patent infringement liability, prosecution history estoppel, § 4:77
- Patent owner estoppel, § 5:16
- Real parties in interest and privity, § 5:14
- Scope of estoppel, § 5:15

EXCLUSIVITY

- FDA approval process, provisions impacting biosimilars, § 3:17 to 3:20

EX PARTE APPLICATION

- Discovery, foreign litigation, § 7:3

FDA APPROVAL

- Generally, § 3:1
- Application Types (this index)
- Process
 - generally, § 3:16 to 3:24
 - citizen petitions, § 3:23
 - complete response letters, § 3:24
 - exclusivity provisions impacting biosimilars, § 3:17 to 3:20
 - Licensure, conditions of use, licensed reference product, § 3:21
 - naming, § 3:22
 - orphan drug exclusivity, § 3:20
 - pediatric exclusivity, § 3:19
 - reference product exclusivity, § 3:18
 - review timeline, § 3:16 to 3:24

FIRST WAVE LITIGATION

- Commencement of suit, limitation on claims, § 4:53
- Patent dance, § 4:19, 4:20

FOREIGN MATTERS

- Discovery in the US for use in foreign litigation. Discovery (this index)
- International Trade Commission (ITC) (this index)
- Patent infringement liability, products manufactured abroad using domestically patented process, § 4:75
- Venue, foreign defendants, § 4:36

FRAUD

- Antitrust actions, intellectual property acquisition and enforcement, walker process, § 8:4

INJUNCTIONS

- Permanent injunctive relief, § 4:97

INJUNCTIONS—Cont’d

Preliminary Injunctions (this index)

INSPECTIONS

Post-licensure requirements, establishment inspection, § 3:25

INTERCHANGEABILITY

Abbreviated biologics license applications (aBLAs), § 3:11, 3:12

INTERNATIONAL TRADE COMMISSION (ITC)

Comparison between Section 337 investigations and district court litigations, § 6:4

Elements of Section 337 violation, § 6:2

Remedies, § 6:3

Section 337 actions, § 6:1 to 6:4

JOINDER

Post-grant proceedings, § 5:18

JURISDICTION

Discretionary exercise of declaratory judgment jurisdiction, § 4:50

Personal, § 4:41

Product liability claims, primary jurisdiction, § 9:5

Subject matter, § 4:40

JURY TRIAL

Generally, § 4:55 to 4:57

Biosimilar v. biosimilar patent cases, § 4:57

BPCIA cases, § 4:56

Right to, § 4:55 to 4:57

LABELING

Product liability claims, FDA biosimilar labeling, § 9:2

LICENSE

Fda approval process, conditions of use, licensed reference product, § 3:21

MANUFACTURING

Abbreviated biologics license applications (aBLAs), manufacturing information, § 3:7

BPCIA, discovery, manufacturing information, § 4:62

Product liability claims, manufacturing defect claims, § 9:3

MANUFACTURING PATENTS

Prosecution of biologic patents, § 1:4

MARKET EXCLUSIVITY

Prosecution of biologic patents, BPCIA, § 1:2

MOTIONS

Stay, § 5:12

NAMES AND NAMING

FDA approval process, § 3:22

NEGOTIATION

Patent dance, § 4:19, 4:20

NOTICE OF COMMERCIAL MARKETING (NCM)

Generally, § 4:22 to 4:31

Second wave litigation

generally, § 4:28 to 4:31

appearance of, § 4:31

factors impacting bringing suit after NCM provided, § 4:30

who can bring suit after applicant provides NCM, § 4:29

Statute governing NCM

generally, § 4:23 to 4:27

enforcement of NCM provisions, § 4:26

requirements for providing NCM, § 4:25

timing of NCM, § 4:24

Timing of NCM, § 4:24

INDEX

OBVIOUSNESS

- Double patenting, obviousness-type, § 4:85
- Ineligible subject matter, § 4:83
- Validity, § 4:83, 4:85

ORPHAN DRUGS

- FDA approval process, orphan drug exclusivity, § 3:20

PATENT DANCE

- 3A statement, § 4:14
- 3B statement by biosimilar applicant
 - generally, § 4:15 to 4:17
 - detailed statement, § 4:17
 - list, § 4:16
- 3C statement by RPS, § 4:18
- Generally, § 4:2 to 4:20
- Confidential information, protection
 - generally, § 4:8 to 4:13
 - enforceability, § 4:13
 - prosecution bar, § 4:10
 - recipients of confidential information, § 4:9 to 4:11
 - regulatory bar, § 4:11
 - use during and after patent dance, § 4:12
- Disclosure of product information to RPS
 - generally, § 4:3 to 4:7
 - additional requested information, § 4:7
 - consequences of failure to provide, § 4:6
 - copy of aBLA, § 4:4
 - “such other information,” § 4:5
- First wave of litigation, § 4:19, 4:20
- Negotiation, § 4:19, 4:20
- Reference product sponsor (RPS)
 - disclosure of product information to RPS, above statements, § 4:14, 4:18
- Unenforceability allegations, § 4:88, 4:89

PATENT INFRINGEMENT

- Prosecution of biologic patents, BPCIA, § 1:1

PATENT INFRINGEMENT LIABILITY

- Generally, § 4:69 to 4:79
- Claim construction, § 4:70
- Direct infringement, literal, § 4:71
- Doctrine of equivalents, § 4:76
- Enforceability
 - generally, § 4:86 to 4:89
 - inequitable conduct, § 4:88
 - unclean hands, § 4:87
 - unenforceability allegations in BPCIA patent dance, § 4:89
- Ensnarement, § 4:78
- Indirect infringement
 - generally, § 4:72 to 4:78
 - contributory infringement, § 4:74
 - doctrine of equivalents, § 4:76
 - ensnarement, § 4:78
 - induced infringement, § 4:73
 - products manufactured abroad using domestically patented process, § 4:75
 - prosecution history estoppel, § 4:77
 - safe harbor, § 4:79
- Literal direct infringement, § 4:71
- Safe harbor, § 4:79
- Validity of patent. Validity (this index)

PEDIATRICS

- FDA approval process, pediatric exclusivity, § 3:19

POST-GRANT PROCEEDINGS

- Generally, § 5:1 to 5:20
- Appeals, § 5:20
- Estoppel (this index)
- Joinder, § 5:18
- Parallel post-grant proceedings and BPCIA litigations, § 5:3
- Serial petitions, § 5:19

POST-GRANT PROCEEDINGS

—Cont'd

Settlement, § 5:17

Stays (this index)

**POST-LICENSE
REQUIREMENTS**

Additional requirements, § 3:28

Establishment inspection, § 3:25

Product changes, § 3:26

Promotional labeling and advertising considerations for prescription biological reference, biosimilar and interchangeable biosimilar products, § 3:27

PREEMPTION

Product liability claims, field preemption, § 9:5

PRELIMINARY INJUNCTIONS

Generally, § 4:58

Expedited discovery, § 4:64

PRODUCT LIABILITY CLAIMS

Generally, § 9:1 to 9:5

Failure to warn claims, § 9:1

Field preemption, § 9:5

Labeling, FDA biosimilar labeling, § 9:2

Manufacturing defect claims, § 9:3

Primary jurisdiction, § 9:5

Product design defect claims, § 9:4

**PROSECUTION OF BIOLOGIC
PATENTS**

Generally, § 1:1 to 1:11

Biosimilars, patent term extension, § 1:11

Continued prosecution, § 1:10

Enablement, section 112, § 1:7

Manufacturing patents, method of, § 1:4

Nonobviousness, section 103, § 1:6

Novelty, section 102, § 1:5

PROSECUTION OF BIOLOGIC

PATENTS—Cont'd

Overlap with market exclusivity, BPCIA, § 1:2

Patent infringement under, BPCIA, § 1:1

Protection to pursue, scope of, § 1:3

Support for antibody patents, section 112, § 1:9

Written description, section 112, § 1:8

PROTECTIVE ORDERS

Generally, § 4:65 to 4:68

Confidentiality tiers, § 4:68

Prosecution bars, § 4:66

Regulatory bars, § 4:67

REFERENCE PRODUCTS

Abbreviated biologics license applications (aBLAs), consequences of comparison, § 3:10

FDA approval process, reference product exclusivity, § 3:18

Reference product sponsor (RPS) Declaratory Judgment Action (this index)

Patent Dance (this index)

REMEDIES

Generally, § 4:90 to 4:98

Conforming amendments of BPCIA, § 4:91

Delaying effective date of FDA approval, § 4:92

Enforceability of patent at-risk launch, § 4:95
attorneys' fees, § 4:96
monetary damages, § 4:94, 4:95
pre-market activity, § 4:94
safe harbor, § 4:94

Injunctions (this index)

ITC remedies, § 6:3

Limitations on remedies, § 4:98

Monetary damages, enforceability of patent, § 4:94, 4:95

INDEX

REMEDIES—Cont'd

- Monetary relief, § 4:93 to 4:95
- Settlement of BPCIA litigation, § 4:99

SAFE HARBOR

- Patent infringement liability, § 4:79
- Remedies, enforceability of patent, § 4:94

SECOND WAVE LITIGATION

- Commencement of suit, limitation on claims, § 4:54
- Notice of Commercial Marketing (NCM) (this index)

SERIAL PETITIONS

- Post-grant proceedings, § 5:19

SETTLEMENT

- Antitrust actions, challenges to patent settlement agreements, § 8:2
- Post-grant proceedings, § 5:17

STANDING

- Commencement of suit, § 4:42

STAYS

- Generally, § 5:4 to 5:11
- Motions to stay, § 5:12
- Simplification of issues, § 5:6
- Stage of litigation, § 5:5
- Undue prejudice
 - generally, § 5:7 to 5:11
 - relationship of parties, § 5:11
 - review request, timing, § 5:8
 - status of review proceedings, § 5:10
 - stay request, timing, § 5:9

TIME AND TIMING

- Declaratory judgment action, right of RPS to bring, § 4:46
- FDA approval process, review timeline, § 3:16 to 3:24
- Notice of commercial marketing (NCM), timing of, § 4:24

TIME AND TIMING—Cont'd

- Remedies, delaying effective date of FDA approval, § 4:92
- Review request, timing, § 5:8
- Scheduling, staging and consolidation, BPCIA, § 4:59
- Scheduling and staging, § 4:60
- Stay request, timing, § 5:9

TRIALS

- Biologics license applications (BLAs), abbreviated applications, § 3:8

UNCLEAN HANDS

- Patent infringement liability, enforceability, § 4:87

VALIDITY

- Generally, § 4:80 to 4:85
- Enablement, lack of, § 4:84
- Indefiniteness, § 4:84
- Ineligible subject matter
 - generally, § 4:81 to 4:83
 - anticipation, § 4:82
 - obviousness, § 4:83
- Obviousness-type double patenting, § 4:85
- Written description, lack of, § 4:84

VENUE

- Generally, § 4:32 to 4:39
- Declaratory judgment, § 4:37 to 4:39
- Patent infringement actions
 - generally, § 4:33 to 4:36
 - declaratory judgment, § 4:38, 4:39
 - defendant's residence, § 4:34
 - foreign defendants, § 4:36
 - infringement, § 4:35
 - place of business, § 4:35

WRITTEN DESCRIPTION

- Validity, lack of written description, § 4:84